



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 07 2006
U.S. PATENT AND TRADEMARK OFFICE
RECEIVED

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/530,512	Charles Keller	1321.2.83.1
INTERNATIONAL APPLICATION NO.		
PCT/US03/32765		
IA. FILING DATE	PRIORITY DATE	
10/15/2003	10/15/2002	
CONFIRMATION NO. 6728		
371 FORMALITIES LETTER		
 *OC000000018030484*		

RECEIVED
MAR 27 2006
MADSON & AUSTIN

Date Mailed: 02/23/2006

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For PatentIn Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for PatentIn Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

DOCKETED
By Sea ON 3/27/06
By _____ ON _____
RESPONSE DUE 4/23/06

DARRELL C COTTMAN

Telephone: (703) 308-9140 EXT 203

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/530,512	PCT/US03/32765	1321.2.83.1


FORM PCT/DO/EO/922 (371 Formalities Notice)



DFW

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 4, 2006.


Eric R. Witt
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	10/530,512	Confirmation No.: 6728
Applicant	:	Charles Keller et al.	
Title	:	HIGH THROUGHPUT DETECTION OF GLUTATHIONE S-TRANSFERASE POLYMORPHIC ALLELES	
Filed	:	April 6, 2005	
TC/A.U.	:	(not yet assigned)	
Examiner	:	(not yet assigned)	
Docket No.	:	1321.2.83.1	
Customer No.	:	21552	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUBMISSION OF AND STATEMENT
REGARDING SEQUENCE LISTING**

Dear Sir:

This paper is being filed in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed February 23, 2006. A substitute paper copy and computer readable copy of the sequence listing are enclosed herewith. This statement is being filed according to 37 CFR 1.821(f). The sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new matter.

A copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures is enclosed.

Respectfully submitted,



Evan R. Witt
Evan R. Witt
Reg. No. 32,512
Attorney for Applicants

Date: April 4, 2006

MADSON & AUSTIN
Gateway Tower West
15 West South Temple, Suite 900
Salt Lake City, Utah 84101
Telephone: 801/537-1700

